These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 28299600)

  • 21. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Ji YX; Zhang ZF; Lan KT; Nie KK; Geng CX; Liu SC; Zhang L; Zhuang XJ; Zou X; Sun L; Zhang ZC
    Chin Med Sci J; 2014 Mar; 29(1):7-14. PubMed ID: 24698672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
    Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
    Zhao P; Chen D; Chen W; Yin XY; Yang D; Liang LJ
    Zhonghua Wai Ke Za Zhi; 2012 Jun; 50(6):514-7. PubMed ID: 22943944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
    Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
    BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Zhu AX; Rosmorduc O; Evans TR; Ross PJ; Santoro A; Carrilho FJ; Bruix J; Qin S; Thuluvath PJ; Llovet JM; Leberre MA; Jensen M; Meinhardt G; Kang YK
    J Clin Oncol; 2015 Feb; 33(6):559-66. PubMed ID: 25547503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Longo L; de Freitas LBR; Santos D; Grivicich I; Álvares-da-Silva MR
    Dig Dis; 2018; 36(5):377-384. PubMed ID: 30007984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
    Suzuki E; Kaneko S; Okusaka T; Ikeda M; Yamaguchi K; Sugimoto R; Aramaki T; Asagi A; Yasui K; Sano K; Hosokawa A; Kato N; Ishii H; Sato T; Furuse J
    Jpn J Clin Oncol; 2018 Apr; 48(4):317-321. PubMed ID: 29474553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib: from literature to clinical practice.
    Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 33. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
    Zugazagoitia J; Manzano A; Sastre J; Ladero JM; Puente J; Díaz-Rubio E
    Clin Transl Oncol; 2013 Feb; 15(2):146-53. PubMed ID: 22875650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
    Ohki T; Sato K; Yamagami M; Ito D; Yamada T; Kawanishi K; Kojima K; Seki M; Toda N; Tagawa K
    Clin Drug Investig; 2015 Nov; 35(11):751-9. PubMed ID: 26446004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    da Fonseca LG; Barroso-Sousa R; Bento Ada S; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
    Med Oncol; 2014 Nov; 31(11):264. PubMed ID: 25273866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
    Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
    Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.